CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer

Small cell lung cancer (SCLC) is characterised by high relapse rates. Tumour-initiating cells (TICs) are responsible for drug resistance and recurrence of cancer. Rovalpituzumab tesirine (Rova-T), a potent humanised antibody–drug conjugate, selectively targets delta-like protein 3, which is highly e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindner, Daniel J., Wildey, Gary, Parker, Yvonne, Dowlati, Afshin, Stark, George R., De, Sarmishtha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921085/
https://www.ncbi.nlm.nih.gov/pubmed/33257843
http://dx.doi.org/10.1038/s41416-020-01192-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921085/
https://www.ncbi.nlm.nih.gov/pubmed/33257843
http://dx.doi.org/10.1038/s41416-020-01192-x

Ejemplares similares